- Home
- IGI vs AGEN Comparison
IGI vs AGEN Comparison
Compare IGI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGI
- AGEN
- Stock Information
- Founded
- IGI 2009
- AGEN 1994
- Country
- IGI United States
- AGEN United States
- Employees
- IGI N/A
- AGEN N/A
- Industry
- IGI Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IGI Finance
- AGEN Health Care
- Exchange
- IGI Nasdaq
- AGEN Nasdaq
- Market Cap
- IGI 97.9M
- AGEN 52.6M
- IPO Year
- IGI N/A
- AGEN 2000
- Fundamental
- Price
- IGI $16.32
- AGEN $3.04
- Analyst Decision
- IGI
- AGEN Buy
- Analyst Count
- IGI 0
- AGEN 4
- Target Price
- IGI N/A
- AGEN $8.00
- AVG Volume (30 Days)
- IGI 33.9K
- AGEN 814.8K
- Earning Date
- IGI 01-01-0001
- AGEN 05-12-2025
- Dividend Yield
- IGI 4.79%
- AGEN N/A
- EPS Growth
- IGI N/A
- AGEN N/A
- EPS
- IGI N/A
- AGEN N/A
- Revenue
- IGI N/A
- AGEN $103,463,000.00
- Revenue This Year
- IGI N/A
- AGEN $4.03
- Revenue Next Year
- IGI N/A
- AGEN $5.57
- P/E Ratio
- IGI N/A
- AGEN N/A
- Revenue Growth
- IGI N/A
- AGEN N/A
- 52 Week Low
- IGI $15.13
- AGEN $1.38
- 52 Week High
- IGI $17.79
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- IGI 53.44
- AGEN 64.52
- Support Level
- IGI $16.21
- AGEN $2.87
- Resistance Level
- IGI $16.37
- AGEN $3.19
- Average True Range (ATR)
- IGI 0.15
- AGEN 0.37
- MACD
- IGI 0.04
- AGEN 0.04
- Stochastic Oscillator
- IGI 86.67
- AGEN 75.00
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).